BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenomOncology Collaborates With Vanderbilt-Ingram Cancer Center For The Commercial Development Of My Cancer Genome Tools


2/10/2014 9:39:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WESTLAKE, Ohio
, Feb. 10, 2014 /PRNewswire/ -- GenomOncology and Vanderbilt-Ingram Cancer Center (VICC) today announced a partnership for the exclusive commercial development of a decision support tool based on My Cancer Genome, an online precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers.

(Logo: http://photos.prnewswire.com/prnh/20140204/CL58248LOGO )

Through this collaboration, GenomOncology and VICC will enhance My Cancer Genome through the development of a new genomics content management tool. The MyCancerGenome.org website will remain free and open to the public. In addition, GenomOncology will develop a decision support tool based on My Cancer Genome data that will enable automated interpretation of mutations in the genome of a patient's tumor, providing actionable results in hours versus days. According to the terms of the agreement, all commercial use of My Cancer Genome in any form will be licensed through GenomOncology.

Vanderbilt-Ingram Cancer Center (VICC) launched My Cancer Genome in January 2011 as an integral part of their Personalized Cancer Medicine Initiative that helps physicians and researchers track the latest developments in precision cancer medicine and connect with clinical research trials. This web-based information tool is designed to quickly educate clinicians on the rapidly expanding list of genetic mutations that impact cancers and enable the research of treatment options based on specific mutations. For more information on My Cancer Genome visit www.mycancergenome.org/about/what-is-my-cancer-genome.

"The future of cancer diagnostics and treatment is genomics-based precision medicine. Therapies based on the specific genetic alterations that underlie a patient's cancer not only result in better outcomes but often have less adverse reactions," commented Manuel Glynias, President and CEO of GenomOncology. "A resource like My Cancer Genome that matches tumor mutations to therapies and makes information accessible and convenient is an incredibly valuable tool. Our collaboration with Vanderbilt-Ingram Cancer Center on My Cancer Genome is designed to keep this resource comprehensive, scalable and easy for clinicians to use."

"We are excited about the opportunity to collaborate with GenomOncology to enhance My Cancer Genome and develop tools for other hospitals, labs and cancer centers to use for patient care," said Mia Levy M.D., Ph.D., co-founder of the My Cancer Genome site. "We believe in the need for high-quality, curated information to educate physicians and give them confidence as they make treatment decisions for patients."

About Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram Cancer Center, a National Cancer Institutedesignated Comprehensive Cancer Center, conducts basic, translational, and clinical research that offers adult and pediatric oncology treatment. VICC is a member of the National Comprehensive Cancer Network along with 22 other leading centers working together to improve quality and effectiveness of cancer care.For more information about VICC and precision medicine visit www.vicc.org.

About GenomOncology

GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed GO Clinical Workbench, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient's tumor genome into an actionable clinical report. GenomOncology's research platform, GenomAnalytics, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company's website at www.genomoncology.com.

For more information regarding this announcement, please contact:
Jane Krug, PR Contact
Phone: 504-390-5935
Email: jane@genomoncology.com

SOURCE GenomOncology



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES